The induction of oxazolone-specific T suppressor afferent cells in mice by hapten-modified isologous IgG. 1984

J Marcinkiewicz, and M Bereta, and J Malinowski, and W Ptak

Injection of isologous 4(ethoxymethylene)-2-phenyl-oxazolin-5-one (oxazolone; OX)-substituted thymocytes or OX-labeled IgG (OX-IgG) into mice produces specific unresponsiveness in which immunization with homologous (OX), but not heterologous (picryl chloride), hapten on the skin does not result in significant contact sensitization. However, while injection of OX-substituted thymocytes triggers suppressor cells which inhibit the effector stage of contact sensitivity reaction, OX-IgG induces cells which suppress exclusively the afferent stage of reaction. In contrast to OX-IgG, OX-substituted F(ab')2 fragments, IgM, and albumin are ineffective. T suppressor afferent cells have Ly-2 and I-J surface markers and their precursors are resistant to cyclophosphamide treatment and adult thymectomy. We assume that T suppressor afferent cells recognize antigen in conjunction with intact IgG molecules, although the exact mechanism is unclear.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008297 Male Males
D010080 Oxazoles Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions. Oxazole,1,3-Oxazolium-5-Oxides,Munchnones,1,3 Oxazolium 5 Oxides
D010081 Oxazolone Immunologic adjuvant and sensitizing agent. 2-Phenyl-4-(ethoxymethylene)oxazol-5-one,4-Ethoxymethylene-2-phenyloxazolone,4 Ethoxymethylene 2 phenyloxazolone
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006241 Haptens Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response. Hapten,Contact-Sensitizing Agents,Agents, Contact-Sensitizing,Contact Sensitizing Agents
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D050378 T-Lymphocytes, Regulatory CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells. Regulatory T Cell,Regulatory T-Cell,Regulatory T-Lymphocyte,Regulatory T-Lymphocytes,Suppressor T-Lymphocytes, Naturally-Occurring,T-Cells, Regulatory,Th3 Cells,Tr1 Cell,Treg Cell,Regulatory T-Cells,Suppressor T-Cells, Naturally-Occurring,Tr1 Cells,Treg Cells,Cell, Regulatory T,Cell, Th3,Cell, Tr1,Cell, Treg,Cells, Regulatory T,Cells, Th3,Cells, Tr1,Cells, Treg,Naturally-Occurring Suppressor T-Cell,Naturally-Occurring Suppressor T-Cells,Naturally-Occurring Suppressor T-Lymphocyte,Naturally-Occurring Suppressor T-Lymphocytes,Regulatory T Cells,Regulatory T Lymphocyte,Regulatory T Lymphocytes,Suppressor T Cells, Naturally Occurring,Suppressor T Lymphocytes, Naturally Occurring,Suppressor T-Cell, Naturally-Occurring,Suppressor T-Lymphocyte, Naturally-Occurring,T Cell, Regulatory,T Cells, Regulatory,T Lymphocytes, Regulatory,T-Cell, Naturally-Occurring Suppressor,T-Cells, Naturally-Occurring Suppressor,T-Lymphocyte, Regulatory,Th3 Cell

Related Publications

J Marcinkiewicz, and M Bereta, and J Malinowski, and W Ptak
January 1981, Immunobiology,
J Marcinkiewicz, and M Bereta, and J Malinowski, and W Ptak
November 1976, Journal of immunology (Baltimore, Md. : 1950),
J Marcinkiewicz, and M Bereta, and J Malinowski, and W Ptak
August 1975, Cellular immunology,
J Marcinkiewicz, and M Bereta, and J Malinowski, and W Ptak
July 1989, Biulleten' eksperimental'noi biologii i meditsiny,
J Marcinkiewicz, and M Bereta, and J Malinowski, and W Ptak
October 1984, Scandinavian journal of immunology,
J Marcinkiewicz, and M Bereta, and J Malinowski, and W Ptak
April 1988, Infection and immunity,
J Marcinkiewicz, and M Bereta, and J Malinowski, and W Ptak
April 1981, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!